Pomalidomide in the management of relapsed multiple myeloma.

Abstract

Pomalidomide, a very potent member of the immunomodulatory drug family, is considered a standard of care for patients with relapsed and refractory myeloma, who have previously been treated with bortezomib and lenalidomide. Pomalidomide induces both direct myeloma cell death, and indirect antimyeloma response through its impact on the microenvironment… (More)
DOI: 10.2217/fon-2016-0184

Topics

  • Presentations referencing similar topics